Data for Dermaseptin B2’s Anti-Proliferative Activity and down Regulation of Anti-Proliferative, Angiogenic and Metastatic Genes in Rhabdomyosarcoma RD Cells in Vitro

This data was obtained from the anti-proliferative activity of of Dermaseptin B2 (Drs B2) and Doxorubicin against Rhabdomyosarcoma (RD) and Vero cells and gene expression analysis of MYC, GFGFR1, NOTCH1, and CXCR7. Treatments were performed through time intervals of 24, 48, and 72-hours. Cell viability data can be obtained by using resazurin reduction assay at 24, 48, and 72-hours intervals. Gene expression data can be obtained by analyzing relative gene expression of MYC, FGFR1, NOTCH1 and CXCR7 at treatment intervals of 24, 48 and 72-hours by comparing treated and treated cells and normalization to beta-acting housekeeping reference gene using qTRPCR with Luna universal qPCR master mix.